Before Covid-19 came along investors were looking to several Nash catalysts in 2020, and yesterday Akero delivered on one of these.
As Smiths Group delays its split partly so it can focus on ventilator production, the US FDA grants emergency authorisation to other breathing devices to treat Covid-19.
A negative reaction to positive migraine data sends Biohaven down.
Amarin’s loss of a crucial patent lawsuit shows that potential buyers were right to be wary of the Vascepa opportunity.
The failures of two bought-in assets leave a third hopelessly exposed to the Covid-19 lockdown.
Merck & Co and Bayer’s vericiguat was deemed another “win” for heart failure at a medical conference this weekend. But widespread use looks unlikely.
Though the stage is apparently set for Bristol’s contingent value right to pay out, the instrument trades at depressed levels.
Good news for patients whose cough is not caused by Covid-19: Merck’s chronic cough pill is a step closer to market. But tolerability questions remain.
A Vantage analysis suggests which small biotechs might seriously have to rethink R&D spending plans in the wake of Covid-19.
IGM's Dan Chen, an expert on coronaviruses, speaks about the value of different ways of trying to treat Covid-19.
Silence has received an important validation, but making progress could be tough.
All of Vantage's Covid-19 stories in one place: share price reactions, clinical trial delays, cost estimates, and more. This page will be updated as our coverage…
As Lilly pauses much of its research owing to the coronavirus pandemic, Vantage takes a look at an estimate of the cash committed to ongoing clinical studies. Clue: it’s…
Cytomx’s bispecific Probody approach attracts Astellas in a deal with a seemingly high up-front payment.
The coronavirus pandemic notwithstanding, Curadev snares its second Sting partner.
A Vantage analysis of FDA decisions expected in the next month and how the ongoing Covid-19 pandemic could affect these.
A Vantage analysis identifies 315 pivotal trials that, like Lexicon’s Scored and Soloist studies, risk never being completed.
Two acquisitions of cell therapy companies could take them in almost opposite directions.
Investors are homing in on biopharma companies able to make real contributions to the coronavirus pandemic, but market frothiness is far from over.
Hints of activity, generated by academic centres, suggest that antivirals and an antimalarial might play some role against Covid-19.